Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will present a corporate overview at the Pulmonary/Lung Disease Mini-Symposium, a part of RBC’s Biotech Expert Insights Series.
Details of the virtual presentation:
Date: Friday, October 7, 2022
Time: 10:20 a.m. ET | 7:20 a.m. PT
Fireside Chat: https://www.veracast.com/webcasts/rbc/lung2022/568XeZ.cfm
The RBC Mini-Symposium will include company presentations and sessions with key opinion leaders from across several lung disease areas including sarcoidosis, scleroderma, and idiopathic pulmonary fibrosis (IPF).
Interested parties can access the live and replay versions of Pliant’s corporate overview from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time it is made available. Those interested in registering for the KOL sessions should contact their RBC sales representative.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.